HK1066551A1 - Tolerogenic peptides from myelin basic protein - Google Patents
Tolerogenic peptides from myelin basic proteinInfo
- Publication number
- HK1066551A1 HK1066551A1 HK04109379.8A HK04109379A HK1066551A1 HK 1066551 A1 HK1066551 A1 HK 1066551A1 HK 04109379 A HK04109379 A HK 04109379A HK 1066551 A1 HK1066551 A1 HK 1066551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- basic protein
- myelin basic
- peptide
- tolerogenic peptides
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Rehabilitation Therapy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202399.2A GB0202399D0 (en) | 2002-02-01 | 2002-02-01 | Peptide |
| PCT/GB2003/000399 WO2003064464A1 (en) | 2002-02-01 | 2003-01-30 | Tolerogenic peptides from myelin basic protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1066551A1 true HK1066551A1 (en) | 2005-03-24 |
Family
ID=9930251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK04109379.8A HK1066551A1 (en) | 2002-02-01 | 2004-11-27 | Tolerogenic peptides from myelin basic protein |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7071297B2 (pt) |
| EP (1) | EP1474443B1 (pt) |
| JP (1) | JP4559082B2 (pt) |
| KR (1) | KR20040108650A (pt) |
| CN (1) | CN100482685C (pt) |
| AT (1) | ATE477269T1 (pt) |
| AU (1) | AU2003202701B2 (pt) |
| BR (1) | BRPI0307276B8 (pt) |
| CA (1) | CA2473469C (pt) |
| CO (1) | CO5601035A2 (pt) |
| CY (1) | CY1110862T1 (pt) |
| DE (1) | DE60333728D1 (pt) |
| DK (1) | DK1474443T3 (pt) |
| ES (1) | ES2349463T3 (pt) |
| GB (1) | GB0202399D0 (pt) |
| HK (1) | HK1066551A1 (pt) |
| MX (1) | MXPA04007510A (pt) |
| NO (1) | NO332446B1 (pt) |
| NZ (1) | NZ534233A (pt) |
| PL (1) | PL212129B1 (pt) |
| PT (1) | PT1474443E (pt) |
| SI (1) | SI1474443T1 (pt) |
| WO (1) | WO2003064464A1 (pt) |
| ZA (1) | ZA200405546B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
| EP2134176A4 (en) * | 2007-03-30 | 2012-08-29 | Brigham & Womens Hospital | COMPOUNDS AND METHODS FOR ENHANCING MHC CLASS II THERAPIES |
| MX2010004698A (es) * | 2007-10-31 | 2010-05-13 | Apitope Technology Bristol Ltd | Composicion. |
| EP2488196B1 (en) | 2009-10-12 | 2015-12-16 | LIFEBio Laboratories LLC | Composition for treatment of multiple sclerosis |
| JP6017422B2 (ja) | 2010-08-10 | 2016-11-02 | エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） | 赤血球結合療法 |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| ES2874884T3 (es) | 2014-02-21 | 2021-11-05 | Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto | Compuestos terapéuticos dirigidos a la glucosa |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10646589B2 (en) * | 2014-12-24 | 2020-05-12 | Apitope International Nv | Thyroid stimulating hormone receptor peptides and uses thereof |
| WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| EP3565585A1 (en) * | 2017-01-04 | 2019-11-13 | Apitope International NV | Therapeutic method using tolerogenic peptides |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6036957A (en) * | 1990-03-30 | 2000-03-14 | Autoimmune, Inc. | Suppression of T-cell proliferation using peptide fragments of myelin basic protein |
| HUT76099A (en) * | 1994-05-10 | 1997-06-30 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis |
| AU4278296A (en) * | 1994-10-25 | 1996-05-15 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
| HU229377B1 (hu) * | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
-
2002
- 2002-02-01 GB GBGB0202399.2A patent/GB0202399D0/en not_active Ceased
-
2003
- 2003-01-30 JP JP2003564084A patent/JP4559082B2/ja not_active Expired - Fee Related
- 2003-01-30 MX MXPA04007510A patent/MXPA04007510A/es active IP Right Grant
- 2003-01-30 EP EP03701612A patent/EP1474443B1/en not_active Expired - Lifetime
- 2003-01-30 PT PT03701612T patent/PT1474443E/pt unknown
- 2003-01-30 BR BRPI0307276A patent/BRPI0307276B8/pt not_active IP Right Cessation
- 2003-01-30 CA CA2473469A patent/CA2473469C/en not_active Expired - Lifetime
- 2003-01-30 DE DE60333728T patent/DE60333728D1/de not_active Expired - Lifetime
- 2003-01-30 CN CNB038030772A patent/CN100482685C/zh not_active Expired - Fee Related
- 2003-01-30 SI SI200331890T patent/SI1474443T1/sl unknown
- 2003-01-30 DK DK03701612.8T patent/DK1474443T3/da active
- 2003-01-30 WO PCT/GB2003/000399 patent/WO2003064464A1/en active Application Filing
- 2003-01-30 AU AU2003202701A patent/AU2003202701B2/en not_active Ceased
- 2003-01-30 PL PL371549A patent/PL212129B1/pl unknown
- 2003-01-30 KR KR10-2004-7011906A patent/KR20040108650A/ko not_active Application Discontinuation
- 2003-01-30 NZ NZ534233A patent/NZ534233A/en not_active IP Right Cessation
- 2003-01-30 AT AT03701612T patent/ATE477269T1/de active
- 2003-01-30 ES ES03701612T patent/ES2349463T3/es not_active Expired - Lifetime
-
2004
- 2004-07-13 ZA ZA2004/05546A patent/ZA200405546B/en unknown
- 2004-07-27 US US10/900,032 patent/US7071297B2/en not_active Expired - Lifetime
- 2004-07-28 NO NO20043210A patent/NO332446B1/no not_active IP Right Cessation
- 2004-08-26 CO CO04083647A patent/CO5601035A2/es not_active Application Discontinuation
- 2004-11-27 HK HK04109379.8A patent/HK1066551A1/xx not_active IP Right Cessation
-
2010
- 2010-10-27 CY CY20101100972T patent/CY1110862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0307276A (pt) | 2004-12-14 |
| DE60333728D1 (de) | 2010-09-23 |
| US20050058643A1 (en) | 2005-03-17 |
| KR20040108650A (ko) | 2004-12-24 |
| AU2003202701B2 (en) | 2009-01-08 |
| PT1474443E (pt) | 2010-10-26 |
| EP1474443B1 (en) | 2010-08-11 |
| ATE477269T1 (de) | 2010-08-15 |
| ES2349463T3 (es) | 2011-01-03 |
| BRPI0307276B8 (pt) | 2021-05-25 |
| NO332446B1 (no) | 2012-09-17 |
| DK1474443T3 (da) | 2010-10-18 |
| GB0202399D0 (en) | 2002-03-20 |
| NO20043210L (no) | 2004-11-01 |
| JP4559082B2 (ja) | 2010-10-06 |
| CO5601035A2 (es) | 2006-01-31 |
| PL212129B1 (pl) | 2012-08-31 |
| CN1625564A (zh) | 2005-06-08 |
| NZ534233A (en) | 2006-04-28 |
| CY1110862T1 (el) | 2015-06-10 |
| PL371549A1 (en) | 2005-06-27 |
| CN100482685C (zh) | 2009-04-29 |
| MXPA04007510A (es) | 2005-07-13 |
| US7071297B2 (en) | 2006-07-04 |
| BRPI0307276B1 (pt) | 2019-08-13 |
| EP1474443A1 (en) | 2004-11-10 |
| JP2005531497A (ja) | 2005-10-20 |
| ZA200405546B (en) | 2005-09-28 |
| SI1474443T1 (sl) | 2010-12-31 |
| CA2473469C (en) | 2012-04-24 |
| CA2473469A1 (en) | 2003-08-07 |
| WO2003064464A1 (en) | 2003-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110862T1 (el) | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης | |
| PH12013500208A1 (en) | Tolerogenic peptides from myelin basic priotein | |
| IL173952A0 (en) | Anti-angiogenic peptides and pharmaceutical compositions based thereon | |
| EA200600128A1 (ru) | Способ уничтожения раковых клеток (варианты), фармацевтическое средство (варианты) и набор для его осуществления | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| DE3584775D1 (de) | Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken. | |
| HUP0001458A2 (hu) | Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása | |
| NO942323L (no) | Soyaprotein eller hydrolysater i farmasöytiske preparater for beskyttelse av bioaktive peptider mot enzymatisk inaktivering | |
| HUP0402160A2 (hu) | T-sejt-epitópok a karboxipeptidáz-G2-ben | |
| WO2006029125A3 (en) | Methods and compositions for treating hypercholesterolemia | |
| MX9700199A (es) | Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20220130 |